Laboratory Corporate Integrity Agreements: What the Reviewer Must Actually Test

A laboratory corporate integrity agreement sets a lab’s continuing compliance duties after a health care fraud settlement. At Precision Toxicology, those duties reach the original order, the test result, the paid claim and the financial relationship behind the referral. For someone working in billing, clinical operations or sales, the important question is whether the account given to the reviewer matches the work happening inside the laboratory.

Why the Settlement Amount Is Only the Starting Point

Precision Toxicology, doing business as Precision Diagnostics, agreed to a $27 million settlement announced in October 2024. The Justice Department alleged that the company promoted custom profiles that generated excessive urine drug testing without an individualized assessment of patients’ needs. It also alleged that Precision supplied free test cups on the condition that physicians send the specimens back for additional testing.

The alleged practices connected the sales offer to the clinical order. A free cup brought the specimen back. A standing profile determined how much testing followed. Medicare, Medicaid and other federal health care programs received the bills. Taxpayers paid for testing the government alleged patients did not need.

Three whistleblower cases led to the settlement, and the government joined in part. Alongside that resolution, Precision signed an agreement with the Department of Health and Human Services Office of Inspector General that reaches the forms, payments and management decisions behind future claims. The settlement announced the payment. The agreement specifies the work that follows.

Laboratory Integrity Agreements Have Different Terms

Precision’s Corporate Integrity Agreement runs for five years from August 22, 2024. Logan Laboratories’ instrument was a three-year Integrity Agreement effective April 14, 2020, according to the OIG agreement listing.

The Office of Inspector General describes the exchange: the entity accepts compliance obligations, and the agency agrees not to seek its exclusion from Medicare, Medicaid and other federal health care programs. The agreement creates an ongoing relationship with the agency, including reports and independent reviews.

Precision’s duties also reach changes in ownership. Its agreement binds purchasers of covered operations and newly acquired or established covered businesses unless the Office of Inspector General agrees otherwise in writing. Before the term ends, Precision must develop a board-approved transition plan for the compliance work that continues afterward.

Independent Review of Test Claims Starts With the Order

Under Precision’s laboratory corporate integrity agreement, independent review of test claims reaches the records that generated the bill. Its reviewer must examine new-client registrations, requisitions or order forms, and applicable test results for patterns inconsistent with medically necessary testing.

That scope gives an account-opening form a place beside the claim. If a practice selected a testing profile when it became a client, the reviewer needs to see what that selection caused the laboratory to perform and bill. The clinical justification belongs to the individual patient whose specimen produced the claim.

The Centers for Medicare & Medicaid Services’ documentation guidance for laboratory services describes the division of work. The treating provider documents medical necessity in the patient’s medical record. The entity billing for the test retains the order, evidence of accurate order processing and claim submission, and the diagnostic information sent to the laboratory.

Custom Profiles Can Turn One Decision Into Repeated Testing

Precision’s settlement allegations centered on custom profiles that functioned as standing orders without individual assessments. The ordering paperwork is therefore part of the conduct the reviewer needs to understand.

The Logan allegations show the same problem inside a different business. Its April 2020 settlement announcement covered $41 million across Logan Laboratories, Tampa Pain Relief Centers and two former executives over allegedly unnecessary urine drug testing.

A whistleblower’s complaint described what a standing authorization allegedly did:

The alleged decision was made when the physician signed the authorization, then carried forward across later specimens. That is why the review reaches beyond the claim to the form that selected the tests.

CMS distinguishes recurring orders specific to an individual patient from routine orders for a population. Its laboratory guidance ties payment to medically necessary services and documentation supporting the patient’s orders. A conditional reflex order can also specify an additional test if the first result meets a condition chosen by the treating clinician. The reviewer needs to see who made the choice, which patient it concerned and what justified the additional testing.

The Result Has to Reach Patient Care

Precision’s internal testing reviews must examine whether ordering providers review results and act on them in patient care. That brings the review back to the clinical purpose of the test.

The agreement requires a testing report identifying the test, patient, ordering provider, order date and reason for testing, including the relevant diagnosis code. Requisition forms must capture that information. Each month, the compliance officer and medical director review the report for missing information and questionable ordering patterns.

Each quarter, the compliance committee joins the compliance officer and medical director to examine trends and outlier providers. That review includes providers whose frequency or patterns appear medically excessive and those who have not regularly reviewed results and acted, as appropriate, to modify care. The compliance officer also identifies claims billed to an inappropriate payer. Findings and corrective action go into the annual report to the Office of Inspector General.

Precision’s review requirements turn attention to whether the ordering provider actually used the information the laboratory produced.

The Medical Director Needs Authority, and Sales Must Answer

Precision’s medical director must be a senior employee reporting directly to the chief executive officer, outside the general counsel’s and chief financial officer’s reporting chains. The agreement requires a physician with experience in pain management and urine drug testing.

The medical director approves practices involving clinical decisions and reports at least quarterly to the chief executive officer, compliance committee and board, with authority to raise clinical matters at any time.

The compliance officer also reports directly to the chief executive officer and has access to the board. Those reporting lines put clinical and compliance concerns in front of the people running the business.

Sales has its own obligation. Precision’s vice president of sales is among the managers required to monitor their departments and certify compliance annually. A manager unable to certify must explain why in writing.

The Referral Arrangement Has to Survive Review Too

Precision’s agreement requires review of financial relationships involving actual or potential sources and recipients of referrals. The review reaches what the parties exchanged and whether promised services actually occurred.

For the relationships the agreement calls Focus Arrangements, Precision must track the parties, approvals and compensation. It must document the business rationale and fair market value and track the services actually provided.

Each year, the independent reviewer examines a random selection of arrangements entered into or renewed during that reporting period. It compares the agreement’s terms with actual performance: what services, items or space were provided, what was paid and when. It also tests whether the required review and approval occurred before payment.

That is a concrete examination of a referral relationship. The payment record shows what the laboratory gave in return. In a case alleging free supplies tied to future testing, those records explain how the specimen reached the laboratory in the first place.

Who Reviews the Reviewer?

Precision engages its Independent Review Organization, but the Office of Inspector General can reject the selection or require a replacement when qualifications, independence or performance fall short.

Sampling requires statistical expertise. Coding review requires a recognized coding certification. Medical-necessity decisions require appropriately qualified licensed healthcare professionals.

The claims reviewer must certify professional independence and objectivity and disclose current and prior engagements with Precision. The lab must provide accurate, complete records and access to the personnel needed for the reviews.

The Office of Inspector General can obtain the reviewer’s work papers, supporting documents, correspondence and draft reports. It also retains rights to inspect records, conduct on-site reviews and interview consenting personnel. The final report is one part of an examination that the agency can look behind.

How a Sample Becomes a Repayment

Precision’s agreement requires a random sample of 100 paid claims in each of five annual reporting periods. The review covers medical necessity, documentation, coding, submission and reimbursement. The paid-claim definition covers Medicare and Medicaid payments, including managed care, and the agency can narrow the population reviewed.

The first sample drawn must be used. When Precision cannot produce documentation for a sampled claim, the reviewer counts it as an error and treats the entire reimbursement as an overpayment. The laboratory cannot substitute another claim for the missing file.

Additional documents also leave a trail. If the reviewer accepts supplemental material after completing the initial review, the report must identify it, say when and why it was accepted, and explain how much weight it received. That matters to an insider who knows what the original file contained.

The reviewer uses the findings to estimate the overpayment across the reviewed population. The report gives that estimate with a statistical range, a two-sided 90% confidence interval. Precision must repay the lower end of that range within 60 days of receiving the claims-review report. Its annual report must include documentation of the refund.

The chief executive officer, medical director and compliance officer must inquire into the annual report’s contents before certifying it. Their signatures make the report management’s responsibility.

How Is Laboratory Fraud Detected and Deterred?

Laboratory fraud review connects the order and clinical reason to the result, claim, payment and referral arrangement. Detection comes from examining where those records diverge. Deterrence requires changing the practices that produced the discrepancy and checking whether the correction worked.

The attention to ordering forms has a long history. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described the Office of Inspector General’s voluntary model plan: standardized requisitions with space for the medical necessity of each test, physician acknowledgments for custom profiles, and monitoring of standing orders.

Precision’s agreement adds a detailed way to test the work. Its internal review process must identify risks, implement audit plans, correct problems and assess whether the corrections are effective. A revised form, an audit finding and a certification can be compared with the orders and claims that followed.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Review Misses What You See

If you handle laboratory orders, claims or referral accounts and see standing profiles still driving tests after management says they stopped, speak with our whistleblower experts about what the review missed. We build your strongest laboratory fraud whistleblower case with you and bring in clinical-laboratory whistleblower lawyers who understand medical necessity, billing and referral payments. We stay beside you as your knowledge of the laboratory becomes the evidence that supports your case.